Skip to main content
BFRG
NASDAQ Life Sciences

BullFrog AI Q3 10-Q: Going Concern Persists Despite $5.0M Cash and $7.9M Raised

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.542
Mkt Cap
$10.04M
52W Low
$0.425
52W High
$1.96
52W Position info
27% above low
Off High info
72% below high
Rel. Volume
Market data snapshot near publication time

BFRG sits 27% above its 52-week low of $0.425.

Summary

BullFrog AI's Q3 2026 10-Q keeps the going-concern warning in place even after raising $7.9 million of net stock proceeds, leaving the company dependent on further equity sales and a possible reverse split to hold its Nasdaq listing.


Key Events · Earnings and Guidance · BFRG

  • Going Concern Warning Repeats

    Management states cash and equivalents are not sufficient to fund planned operations for at least a year beyond the filing date, raising substantial doubt about the ability to continue as a going concern.

  • Cash Rises on $7.9M Stock Sales

    Cash and cash equivalents reached $4,989,914 at September 30, 2026 versus $2,183,705 at December 31, 2025, after $7,851,626 of net proceeds from common stock sales, split roughly $5.8 million under the Lincoln Park ELOC and $2.0 million under the BTIG ATM.

  • Q3 Loss Widens as Costs Climb

    Third-quarter net loss was $2,011,881 versus $1,551,612 a year earlier, with G&A up 31% to $1,622,565 and R&D up 27% to $439,240; the nine-month net loss was $4,976,572.

  • Nasdaq Bid-Price Deadline Looms

    The second 180-day compliance period runs to February 8, 2027, and the company has told Nasdaq it intends to cure the sub-$1.00 bid by effecting a reverse split at a ratio between 1-to-2 and 1-to-15 if needed.


Analysis · BFRG · Life Sciences

BullFrog still cannot fund a year of operations from its own cash, so it remains dependent on selling stock through its ATM and Lincoln Park equity line. The quarter bought time, not a cure: cash rose to $4,989,914 from $2,183,705 at year-end on $7,851,626 of net stock sale proceeds, while the nine-month net loss was $4,976,572. Costs are climbing again, with Q3 G&A up 31% and R&D up 27% year over year, which shortens the runway the raise just extended. The Nasdaq bid-price clock runs to February 8, 2027, and management has said it will use a reverse split if the price does not recover on its own.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BFRG was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10M. The 52-week trading range was $0.43 to $1.96. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BFRG - Latest Insights

BFRG
Sep 22, 2026, 4:45 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $0.620
Real-time Price: $0.5415 info
Change: -$0.0785 (-13%) info
Market Cap: $10.04M info
BFRG
Aug 20, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.570
Real-time Price: $0.5415 info
Change: -$0.0285 (-5%) info
Market Cap: $10.04M info
BFRG
Aug 14, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.5891
Real-time Price: $0.5415 info
Change: -$0.0476 (-8%) info
Market Cap: $10.04M info
BFRG
Jul 06, 2026, 4:00 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.698
Real-time Price: $0.5415 info
Change: -$0.1565 (-22%) info
Market Cap: $10.04M info
BFRG
Jun 15, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6387
Real-time Price: $0.5415 info
Change: -$0.0972 (-15%) info
Market Cap: $10.04M info